Expert Interview
Discussing Roche's Overall Survival Results of the Phase III ALEX Study: Alectinib vs. Crizotinib in First-Line ALK-Positive Advanced NSCLC
Ticker(s): RHHBYInstitution: University of Colorado
- Medical Oncologist & Founding Director of the University of Colorado Cancer Center.
- Manages 50+ Patients with NSCLC
- Past president of the International Association for the Study of Lung Cancer (IASLC) and the American Society of Clinical Oncology (ASCO); served as chairman of the FDA Oncology Drug Advisory Committee. Research focuses on novel molecular therapies and immunotherapies for lung cancer and other thoracic cancers.
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Nov 26, 2025
- Call Time
- 10:00 AM EST
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
